Cmax (pharmacology) explained

is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose.[1] It is a standard measurement in pharmacokinetics.

Description

is the opposite of, which is the minimum (or trough) concentration that a drug achieves after dosing. The related pharmacokinetic parameter is the time at which the is observed.[2]

After an intravenous administration, and are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration, and are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject.[3]

Short term drug side effects are most likely to occur at or near the, whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the .

The is often measured in an effort to show bioequivalence (BE) between a generic and innovator drug product.[4] According to the FDA, drug quality bioavailability (BA) and BE rely on pharmacokinetic measurements such as AUC and that are reflective of systemic exposure.[5]

See also

Notes and References

  1. Book: Tracy TS . Stitzel RE, Craig CF . Pharmacokinetics . Modern pharmacology with clinical applications . Hagerstwon, MD . 49 . 2004 . Lippincott Williams & Wilkins . 978-0-7817-3762-3 .
  2. Book: Newlands A . Statistics and Pharmacokinetics in Clinical Pharmacology Studies . SAS Conference Proceedings: Pharmaceutical Users Software Exchange . 2006 . http://www.lexjansen.com/phuse/2006/st/st03.pdf . dead . https://web.archive.org/web/20131113232412/http://www.lexjansen.com/phuse/2006/st/st03.pdf . 2013-11-13 .
  3. Urso R, Blardi P, Giorgi G . A short introduction to pharmacokinetics . European Review for Medical and Pharmacological Sciences . 6 . 2–3 . 33–44 . March 2002 . 12708608 .
  4. Midha KK, Rawson MJ, Hubbard JW . The bioequivalence of highly variable drugs and drug products . International Journal of Clinical Pharmacology and Therapeutics . 43 . 10 . 485–498 . October 2005 . 16240706 . 10.5414/cpp43485 .
  5. Web site: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations . Guidance for Industry . Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration . 18 February 2021 .